Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · May 25, 2023

Cabozantinib Plus Nivolumab and Ipilimumab for Renal Cell Carcinoma

The New England Journal of Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
N. Engl. J. Med 2023 May 11;388(19)1767-1778, TK Choueiri, T Powles, L Albiges, M Burotto, C Szczylik, B Zurawski, E Yanez Ruiz, M Maruzzo, A Suarez Zaizar, LE Fein, FA Schutz, DYC Heng, F Wang, F Mataveli, YL Chang, M van Kooten Losio, C Suarez, RJ Motzer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading